Structure via PubChem · Public domain (PubChem)
PF-219,061
Sign in to savePF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor. It was under development as a potential medication for the treatment of female sexual dysfunction. It did not advance into clinical trials.
In the Vinony graph
Within Vinony's link graph, PF-219,061 is referenced by 1,490 other articles, and connects out to digital object identifier, chemical formula and dopamine.
It sits within the topics 3-Hydroxyphenyl compounds, Abandoned drugs and Aphrodisiacs.
Its subject is documented across 4 Wikipedia language editions.
Chemical data
- Formula
- C13H19NO2
- Molecular weight
- 221.29 g/mol
- IUPAC name
- 3-[(2R)-4-propylmorpholin-2-yl]phenol
- SMILES
- CCCN1CCO[C@@H](C1)C2=CC(=CC=C2)O
- InChIKey
- WYEGTIGJSHGEID-ZDUSSCGKSA-N
- XLogP
- 2.4
- Polar surface area
- 32.7 Ų
- H-bond donors
- 1
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Molecule type
- Small molecule
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 221.141579
Show 4 more facts
- chemical formula
- C₁₃H₁₉NO₂
- canonical SMILES
- CCCN1CCOC(C1)C2=CC(=CC=C2)O
- isomeric SMILES
- CCCN1CCO[C@@H](C1)C2=CC(=CC=C2)O
- Commons category
- PF-219,061
Sources (1)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor. It was under development as a potential medication for the treatment of female sexual dysfunction. It did not advance into clinical trials.
== See also == List of investigational sexual dysfunction drugs ABT-670 ABT-724 Cabergoline Bremelanotide Flibanserin Intrinsa Melanotan II OSU-6162 PF-592,379 Pramipexole Tibolone UK-414,495
Excerpted from Wikipedia’s “PF-219,061” article, available under the CC BY-SA 4.0 licence.